Recognition from top medical journals
Dibifree completed clinical trial at Tri-Service General Hospital
Excellent Clinical Outcome
HbA1c, fasting, and postprandial glucose reduced significantly.
What is more
Body Weight and fat impoved.
Mechanism
Enhanced GLP-1 secretion, inhibition of DPP-4 and α-glucosidase, and improved glucose tolerance
Excellent Clinical Outcome
HbA1c, fasting, and postprandial glucose reduced significantly.
What is more
Body Weight and fat impoved.
Mechanism
Enhanced GLP-1 secretion, inhibition of DPP-4 and α-glucosidase, and improved glucose tolerance
Clicnical Outcome
Dibifree is a natural plant extract.
In the past, drugs that could lower HbA1c were mainly Western medicines, but the emergence of Dibifree has broken this pattern.
★Dibifree significantly lowered HbA1c levels after 3 months of treatment (p ≤0.001) compared to placebo.
★It helps control diabetes by restoring the body's own pancreatic function in a way.
★The added value is the reduction in weight and body fat.
★No Side Effects.
How It Works ?
Workflow
Workflow illustrating the translation validation of Dibifree treatment, beginning with clinical investigation demonstrating HbA1c reduction and weight loss, followed by integration with big data analysis and exploration of underlying biological activities.
Gene Mapping
The network illustrated the top 15 diseases associated with Dibifree signatures, identified using DisGeNET database on Disease Ontology platform. Dot size and color reflect gene counts and p values, respectively.
GLP-1
Effects of Dibifree treatment on GLP-1 secretion under different glucose conditions (Mean ±SEM, n =3).
DPP-4
Inhibition of DPP-4 enzyme activity by Dibifree treatment (Mean ±SEM, n =4). The average IC₅₀ was 503.5 μg/mL in human diabetic plasma and 656.15 μg/mL in bovine serum.